Researchers at the University of Texas MD Anderson Cancer Center have discovered that renal medullary carcinoma (RMC) cells use a process called “myeloid mimicry” to evade the immune system and promote rapid disease progression following immunotherapy treatment. This discovery, published in Nature Communications , came about after a Phase II clinical trial testing a combination therapy of two immune checkpoint inhibitors (ICIs) was halted after all 10 enrolled patients experience rapid disease progression.

“We identified a myeloid mimicry pathway that can drive tumor hyper progression following immunotherapy in renal medullary carcinoma. Inhibiting this pathway may offer a promising strategy to advance into clinical studies,” said Pavlos Msaouel, MD, PhD, one of the lead authors of

See Full Page